Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Amicus, Bloomin' Brands, Seagate and More Friday Afternoon Analyst Calls
12:26pm, Friday, 21'st May 2021
With the trading day more than halfway over, the markets were somewhat mixed going into the weekend.
Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug
02:17pm, Thursday, 20'th May 2021
Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.
Is the Options Market Predicting a Spike in Apellis (APLS) Stock?
09:46am, Wednesday, 19'th May 2021
Investors need to pay close attention to Apellis (APLS) stock based on the movements in the options market lately.
Apellis Pharmaceuticals: Empaveli Approved With A Broad Label
03:19pm, Tuesday, 18'th May 2021
Apellis announced the FDA approval of Empaveli for the treatment of PNH patients.
5 Movers To Look Into For The Rest Of May
10:59am, Tuesday, 18'th May 2021
5 Movers To Look Into For The Rest Of May
Apellis Pharmaceuticals (APLS) Stock: 19.88% Increase Explanation
06:40am, Tuesday, 18'th May 2021
The stock price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) increased by 19.88%. This is why it happened.
Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod
11:17am, Monday, 17'th May 2021
The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.
Apellis Stock Is Trading Higher On FDA Approval For Empaveli In Rare Blood Disorder
07:23am, Monday, 17'th May 2021
The FDA has approved Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Empaveli (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare blood disease t
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S. Fo
Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress
10:06am, Wednesday, 12'th May 2021
WALTHAM, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that seven ab
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 07'th May 2021
WALTHAM, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company
Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus
09:46am, Thursday, 29'th Apr 2021
Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2021 Results - Earnings Call Transcript
12:15am, Thursday, 29'th Apr 2021
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2021 Results - Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Misses Revenue Estimates
06:17pm, Wednesday, 28'th Apr 2021
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -37.28% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for
Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
04:01pm, Wednesday, 28'th Apr 2021
WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first quar
